Improving access to cancer clinical trials by reducing the financial burden

Abstract

Cancer clinical trials are vital to improving cancer care, but participation may add an additional financial burden for individuals and families already struggling to bear the high cost of cancer care. Finding sustainable ways to reduce financial toxicity, particularly for low‐ and middle‐income patients, may help to improve clinical trial recruitment and retention.

Glioblastoma: Emerging Treatments and Novel Trial Designs

“…The inclusion of patients should be encouraged through the development of inter-center networks and improvement of organizational phases. Investments in trial planning and facilities for patients enrolled in clinical trials can increase the number of patients in clinical trials [88][89][90].…”

“…The primary field of improvement is represented by organizational improvement and the need for investment in the research of active compounds, trial planning, and patients on trial tutelage [88][89][90].…”

“…From the organizational point of view, there are several fields of improvement of clinical trials in GBM [88][89][90].…”

Impact of caregivers' psychological and caregiving status on recruitment, conversion, and retention in stem cell therapy trials for cerebral palsy: A prospective survey analysis

“…A previous report showed a moderate correlation between the conduct of paediatric clinical trial activities and the burden of the disease (Bourgeois et al, 2014 ). Another study found that the access of a group of patients with cancer to clinical trials could be improved by reducing the financial burden, especially by taking into account travel costs in low‐income areas (Borno et al, 2018 ; Winkfield, 2020 ). Cameron et al considered using a quantitative patient burden assessment, the Patient Friction Factor (PFC), for clinical trials, to evaluate the feasibility of a clinical trial design (Cameron et al, 2020 ).…”